{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:43:22Z","timestamp":1792035802288,"version":"4.4.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases, National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.antiviral.2018.05.013","type":"journal-article","created":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T12:35:35Z","timestamp":1527856535000},"page":"38-45","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"special_numbering":"C","title":["Galidesivir limits Rift Valley fever virus infection and disease in Syrian golden hamsters"],"prefix":"10.1016","volume":"156","author":[{"given":"Jonna B.","family":"Westover","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Mathis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ray","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luci","family":"Wandersee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin W.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Sefing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brady T.","family":"Hickerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kie-Hoon","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William P.","family":"Sheridan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian B.","family":"Gowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2018.05.013_bib1","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2460\/javma.234.7.883","article-title":"Rift Valley fever virus","volume":"234","author":"Bird","year":"2009","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"10.1016\/j.antiviral.2018.05.013_bib2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.antiviral.2017.03.012","article-title":"Antiviral activity of the adenosine analogue BCX4430 against West Nile virus and tick-borne flaviviruses","volume":"142","author":"Eyer","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.05.013_bib3","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/tbed.12608","article-title":"Quantifying the potential pathways and locations of Rift Valley fever virus entry into the United States","volume":"65","author":"Golnar","year":"2017","journal-title":"Trans. Emerg. Dis."},{"key":"10.1016\/j.antiviral.2018.05.013_bib5","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1128\/AAC.00356-07","article-title":"In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections","volume":"51","author":"Gowen","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.05.013_bib6","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1128\/JVI.02341-13","article-title":"Aerosolized rift valley fever virus causes fatal encephalitis in african green monkeys and common marmosets","volume":"88","author":"Hartman","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.05.013_bib7","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3390\/v3050493","article-title":"The pathogenesis of Rift Valley fever","volume":"3","author":"Ikegami","year":"2011","journal-title":"Viruses"},{"key":"10.1016\/j.antiviral.2018.05.013_bib8","doi-asserted-by":"crossref","first-page":"6607","DOI":"10.1128\/AAC.03368-14","article-title":"BCX4430, a novel nucleoside analog, effectively treats yellow fever in a Hamster model","volume":"58","author":"Julander","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2018.05.013_bib9","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.antiviral.2016.11.003","article-title":"Efficacy of the broad-spectrum antiviral compound BCX4430 against Zika virus in cell culture and in a mouse model","volume":"137","author":"Julander","year":"2017","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.05.013_bib10","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.antiviral.2014.03.008","article-title":"One Health approach to Rift Valley fever vaccine development","volume":"106","author":"Kortekaas","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.05.013_bib11","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.virol.2011.09.023","article-title":"Rift Valley fever virus inhibits a pro-inflammatory response in experimentally infected human monocyte derived macrophages and a pro-inflammatory cytokine response may be associated with patient survival during natural infection","volume":"422","author":"McElroy","year":"2012","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2018.05.013_bib12","series-title":"NIAID Emerging Infectious Diseases\/Pathogens","author":"NIAID","year":"2016"},{"key":"10.1016\/j.antiviral.2018.05.013_bib13","first-page":"493","article-title":"A simple method of estimating fifty percent endpoints","volume":"27","author":"Reed","year":"1938","journal-title":"Am. J. Hyg."},{"key":"10.1016\/j.antiviral.2018.05.013_bib14","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.antiviral.2014.01.016","article-title":"Favipiravir (T-705) protects against peracute Rift Valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatment","volume":"104","author":"Scharton","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2018.05.013_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116722","article-title":"Rift Valley fever virus infection in golden Syrian hamsters","volume":"10","author":"Scharton","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2018.05.013_bib16","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1128\/JVI.06190-11","article-title":"Development of a novel nonhuman primate model for Rift Valley fever","volume":"86","author":"Smith","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.05.013_bib17","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jiph.2016.04.002","article-title":"BCX4430 - a broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease","volume":"9","author":"Taylor","year":"2016","journal-title":"J. Inf. Public Health"},{"key":"10.1016\/j.antiviral.2018.05.013_bib18","doi-asserted-by":"crossref","first-page":"502","DOI":"10.2987\/08-5791.1","article-title":"Potential for North American mosquitoes to transmit Rift Valley fever virus","volume":"24","author":"Turell","year":"2008","journal-title":"J. Am. Mosq. Contr. Assoc."},{"key":"10.1016\/j.antiviral.2018.05.013_bib19","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature13027","article-title":"Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430","volume":"508","author":"Warren","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.antiviral.2018.05.013_bib20","series-title":"2018 annual Review of the Blueprint List of Priority Diseases","author":"WHO","year":"2018"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218301499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354218301499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T22:56:54Z","timestamp":1535583414000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354218301499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":19,"alternative-id":["S0166354218301499"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.05.013","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Galidesivir limits Rift Valley fever virus infection and disease in Syrian golden hamsters","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}